UCB Research Inc.
840 Memorial Drive
Cambridge
Massachusetts
02139
U.S.A.
Phone:
Fax:
617-547-8481
|
UCB Research, Inc., located in Cambridge, Massachusetts, is a cutting edge research and discovery company which supports UCB Pharma's drug development pipeline with therapeutic candidates for allergic and central nervous system disorders. Our research utilizes state-of-the-art tools for target discovery, chemistry and pharmacology. We maintain an entrepreneurial environment that encourages personal initiative. Therefore, we have created a dynamic and innovative working environment with a broad range of drug discovery capabilities.
UCB Research is a subsidiary of UCB Pharma, a global research-based pharmaceutical company with 6,500 employees based in Brussels, Belgium and with U.S. headquarters in Atlanta, Georgia. The company is a global leader in the research, manufacture, and marketing of innovative therapeutics for allergy and central nervous system disorders. UCB Pharma's products include Zyrtec® (ceterizine HCl), globally the leading antihistamine, and Keppra® (levetiracetam), a novel anti-epileptic drug approved in the U.S. and Europe in 2000.
UCB Pharma is part of the UCB Group, which in addition to pharmaceuticals, includes a films and coatings sector, Surface Specialties. UCB Group currently employs over 10,000 people worldwide. The company's two sectors seek to promote health, well being and an improved quality of life.
Last Updated: 03-11-05
Email:
Ownership:
Web Site:
UCB Research Inc.
Employees:
100 (Cambridge) 10,000 (Globally)
Symbol:
|